Ideaya Biosciences Inc (IDYA)

Dec 21, 2024

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Shares Bought by Barclays PLC - MarketBeat

Dec 21, 2024

Dec 20, 2024

Wellington Management Group LLP Lowers Stock Position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - MarketBeat

Dec 20, 2024

Dec 19, 2024

IDEAYA Biosciences (NASDAQ:IDYA) Sets New 52-Week LowHere's Why - MarketBeat

Dec 19, 2024

Dec 19, 2024

IDEAYA Biosciences Announces Late-Breaker Oral Presentation of IDE397 Phase 1 Expansion Results in MTAP-Deletion Lung and Urothelial Cancer at the 36th Edition of the EORTC-NCI-AACR Symposium - The Eastern Progress Online

Dec 19, 2024

Dec 18, 2024

IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer - The Eastern Progress Online

Dec 18, 2024

Dec 17, 2024

Ideaya Biosciences keeps stock target, Outperform on robust medicine pipeline - Investing.com Canada

Dec 17, 2024

Dec 17, 2024

IDEAYA Biosciences (NASDAQ:IDYA) Receives "Overweight" Rating from Cantor Fitzgerald - MarketBeat

Dec 17, 2024

Dec 17, 2024

Short Interest in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Declines By 11.2% - MarketBeat

Dec 17, 2024

Dec 17, 2024

IDEAYA Biosciences (NASDAQ:IDYA) Receives "Outperform" Rating from Wedbush - MarketBeat

Dec 17, 2024

Dec 17, 2024

IDEAYA Announces IDMC Recommendation of Move-Forward Dose in Par - GuruFocus.com

Dec 17, 2024

Dec 17, 2024

IDEAYA Announces IDMC Recommendation of Move-Forward Dose in Part 2a of Registration-Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA-A2-Negative Metastatic Uveal Melanoma - Quantisnow

Dec 17, 2024

Dec 17, 2024

IDEAYA Announces Development Candidate Nomination of IDE251, a Potential First-in-Class KAT6/7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung Cancers - The Malaysian Reserve

Dec 17, 2024

Dec 16, 2024

IDEAYA nominates IDE251 for cancer treatment development By Investing.com - Investing.com South Africa

Dec 16, 2024

Dec 16, 2024

IDEAYA Announces Agenda for Investor R&D Day Webcast on December 16, 2024 - PR Newswire

Dec 16, 2024

Dec 16, 2024

IDEAYA nominates IDE251 for cancer treatment development - Investing.com

Dec 16, 2024

Dec 16, 2024

IDEAYA Announces Development Candidate Nomination of IDE251, a Potential First-in-Class KAT6/7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung Cancers – Company Announcement - Financial Times

Dec 16, 2024

Dec 16, 2024

IDEAYA Biosciences (NASDAQ:IDYA) pulls back 9.2% this week, but still delivers shareholders solid 23% CAGR over 5 years - Yahoo Finance

Dec 16, 2024

Dec 16, 2024

Indo-Asian News Service - IANS India Pvt Ltd

Dec 16, 2024

Dec 16, 2024

State Street Corp Boosts Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - MarketBeat

Dec 16, 2024

Dec 16, 2024

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives $53.67 Consensus Price Target from Analysts - MarketBeat

Dec 16, 2024

Dec 15, 2024

(IDYA) Proactive Strategies - Stock Traders Daily

Dec 15, 2024

Dec 14, 2024

IDEAYA Biosciences (NASDAQ:IDYA) Hits New 52-Week LowShould You Sell? - MarketBeat

Dec 14, 2024

Dec 13, 2024

IDEAYA Announces Webcast to Report Interim Phase 2 Data for Darovasertib and Regulatory Update from FDA Type C Meeting in Neoadjuvant Uveal Melanoma on Monday, September 23, 2024 - Kilgore News Herald

Dec 13, 2024

Dec 13, 2024

IDEAYA Biosciences to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference - The Eastern Progress Online

Dec 13, 2024

Dec 13, 2024

Ideaya Biosciences stock hits 52-week low at $25.16 - Investing.com India

Dec 13, 2024

Dec 13, 2024

Ideaya Biosciences stock hits 52-week low at $25.16 By Investing.com - Investing.com UK

Dec 13, 2024

Dec 13, 2024

IDEAYA Biosciences' SWOT analysis: precision oncology stock poised for growth - Investing.com

Dec 13, 2024

Dec 12, 2024

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Eastern Progress Online

Dec 12, 2024

Dec 12, 2024

BNP Paribas Financial Markets Decreases Stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - MarketBeat

Dec 12, 2024

Dec 11, 2024

IDEAYA Biosciences Announces Participation in Upcoming December 2024 Investor Relations Events - Victoria Advocate

Dec 11, 2024

Dec 11, 2024

IDEAYA begins trial of new cancer drug combo By Investing.com - Investing.com Canada

Dec 11, 2024

Dec 10, 2024

IDEAYA Biosciences Announces Participation in Jefferies London Healthcare Conference and Plans for Investor R&D Day - The Eastern Progress Online

Dec 10, 2024

Dec 10, 2024

IDEAYA begins trial of new cancer drug combo - Investing.com India

Dec 10, 2024

Dec 10, 2024

IDEAYA Launches Breakthrough Phase 1 Trial: Novel PARG Inhibitor + KEYTRUDA for Endometrial Cancer - StockTitan

Dec 10, 2024

Dec 10, 2024

IDEAYA Biosciences Announces Development Candidate Nomination of IDE892, a Potential Best-in-Class MTA-cooperative PRMT5 Inhibitor - Marketscreener.com

Dec 10, 2024

Dec 09, 2024

Ideaya nominates IDE-892 as development candidate - BioWorld Online

Dec 09, 2024

Dec 09, 2024

IDEAYA Biosciences Unveils IDE892, Breakthrough Cancer Drug Candidate with Promising Preclinical Results - StockTitan

Dec 09, 2024